Key result
Among elderly men with prostate cancer, depression during the treatment phase was associated with an increased risk of death and higher healthcare utilization.
Why the study?
Does depression increase health resource utilization, costs, and mortality in elderly patients with prostate cancer?
Cohort (n=50,147)
Yes
Does depression increase health resource utilization, costs, and mortality in elderly patients with prostate cancer?
Depression in elderly men with prostate cancer is associated with significantly increased healthcare utilization, costs, and mortality.
Answers are grounded in this paper and cite their sources.
May identify high-risk elderly prostate cancer patients; hypothesis-generating for whether depression treatment improves survival or lowers utilization.
OBJECTIVE: We sought to analyze the prevalence and incremental burden of depression among elderly with prostate cancer. METHODS: We adopted a retrospective cohort design using the Surveillance, Epidemiology and End Results-Medicare linked database between 1995 and 2003. Patients with prostate cancer diagnosed between 1995 and 1998 were identified and followed retrospectively for 1 year pre-diagnosis and up to 8 years post diagnosis. In this cohort of patients with prostate cancer, depression during treatment phase (1 year after diagnosis of prostate cancer) or in the follow-up phase was identified using the International Classification of Diseases-Ninth Revision depression-related codes. Poisson, general linear (log-link) and Cox regression models were used to determine the association between depression status during treatment and follow-up phases and outcomes-health resource utilization, cost and mortality. RESULTS: Of the 50,147 patients newly diagnosed with prostate cancer, 4285 (8.54%) had a diagnosis of depression. A diagnosis of depression during treatment phase was associated with higher odds of emergency room visits (odds ratio (OR) = 4.45, 95% CI = 4.13, 4.80), hospitalizations (OR = 3.22, CI = 3.08, 3.37), outpatient visits (OR = 1.71, CI = 1.67, 1.75) and excess risk of death over the course of the follow-up interval (hazard ratio = 2.82, CI = 2.60, 3.06). Health care costs associated with depression remained elevated compared with costs for men without depression, over the course of the follow-up. CONCLUSIONS: Depression during the treatment phase was associated with significant health resource utilization, costs and mortality among men with prostate cancer. These findings emphasize the need to effectively identify and treat depression in the setting of prostate cancer.
No takes yet. Share an insight, caveat, or question.
Jayadevappa et al. (2011) conducted a cohort in Prostate cancer (n=50,147). Depression vs. No depression was evaluated on Mortality (HR 2.82, 95% CI 2.60-3.06). Among elderly men with prostate cancer, depression during the treatment phase was associated with an increased risk of death and higher healthcare utilization.
Synapse has enriched 10 related papers. Consider them for comparative context: